The article
fecal occult blood (FOB) provides an expanded consideration of the clinical application of FOB tests generally, including other clinical methods, and the comments here are those that relate specifically to the guaiac gFOBT method. One major use of stool testing for blood is detection of
colorectal cancer. However, other possible positive results include: gastroesophageal cancer, GI bleeds,
diverticulae,
hemorrhoids,
anal fissures,
colon polyps,
ulcerative colitis,
Crohn's disease,
celiac disease,
GERD,
esophagitis,
peptic ulcers,
gastritis,
inflammatory bowel disease,
vascular ectasias,
portal hypertensive gastropathy,
aortoenteric fistulas,
hemobilia,
endometriosis, and
trauma. The stool guaiac test was originally the principal colon cancer screening technology available, but modern tests which look for
globin or DNA are now also available. Several recent colon cancer screening guidelines have recommended replacing any older low-sensitivity, guaiac-based fecal occult blood testing (gFOBT) with either newer high-sensitivity guaiac-based fecal occult blood testing (gFOBT) or fecal immunochemical testing (FIT), which tests for
globin rather than the
heme detected by the guaiac method. The US Multisociety Task Force (MSTF) looked at 6 studies that compared high sensitivity gFOBT (Hemoccult SENSA) to FIT, and concluded that there were no clear difference in overall performance between these methods, and a similar recommendation was made by the National Guideline Clearinghouse (NGC). Results of a single fecal sample should be interpreted cautiously, as there is a high rate of false negativity associated with the test. Using three cards, each on a different day, is recommended to improve sensitivity. The Centers for Disease Control and Prevention (CDC) in a 2006–2007 survey found extensive inappropriate use of low sensitivity gFOBT and of single specimens; it is unclear if these widespread suboptimal approaches have since declined. The Current Procedural Terminology (CPT) coding was changed in January 2006 to include CPT code 82270, which indicates that consecutive collection of three stool samples has occurred, either as three single cards or a single triple card. Since January 2007, the US Medicare program reimburses for colorectal cancer screening with gFOBT only when this code is used. The stool guaiac test method may be preferable to fecal immunochemical testing (FIT) if there is a clinical concern about possible gastric or proximal upper intestinal bleeding. However, although
heme breakdown is less than
globin during intestinal transit, false negative results can be seen with the stool guaiac tests due to degradation of the peroxidase-activity. This can cause false negative results in upper gastrointestinal bleeding sources, or in right colon adenomas and cancers that have comparable blood losses to positively testing left colon lesions. A positive gFOBT with subsequent negative colonoscopy may lead to an upper endoscopy. It is unclear whether this is an effective intervention if there is a positive gFOBT but no anemia. Endoscopy when there is a positive gFOBT along with iron deficiency anemia, or iron deficiency anemia on its own, has a higher rate of finding problems. == References ==